SLC5A2 and type 2 diabetes mellitus: Luseogliflozin could reduce the EAT volume in parallel with the improvement of systemic micro-inflammation and the reduction of body weight in Japanese patients with T2DM and BMI ≥ 25 kg/m2, assuming the possibility that SGLT2 inhibitors may impact cardiovascular risk partly by reducing the EAT volume.